Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.61 |
| ▸ | DRD1 | P21728 | 2/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.61 |
| ▸ | DRD5 | P21918 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5327803 | 0.90 | DRD2 (0.52) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL5318736 | 0.89 | DRD2 (0.51) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL10535651 | 0.81 | DRD1 (0.65) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL29795180 | 0.78 | DRD1 (0.64) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL31714136 | 0.77 | DRD1 (0.59) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL5327927 | 0.77 | DRD2 (0.49) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL3475010 | 0.77 | CHRNA7 (0.90) | CHRNA7 | |
| SCHEMBL14239889 | 0.77 | CHRNA7 (0.90) | CHRNA7 | |
| SCHEMBL22943657 | 0.76 | HDAC6 (0.53) | CHRNA7 | |
| SCHEMBL22943674 | 0.76 | HDAC6 (0.53) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528767-B2 | HDAC6 inhibitors and uses thereof | EIKONIZO THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20220281814-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281814-A1 | HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | DRD2 4714/4885DRD1 4606/4885DRD4 4764/4885 |
| US-12528767-B2 | HDAC6 inhibitors and uses thereof | HDAC6, HDAC1, HDAC11 | DRD2 4094/4885DRD1 3882/4885DRD4 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.